Nutritional Supplementation With Agmatine Sulfate During Small Fiber Neuropathy

JFK Medical Center15 enrolled

Overview

This is a nonblinded Case-only study that evaluates the effects of Agmatine Sulfate on small fiber peripheral neuropathy. Patients will be started on Agmatine sulfate (a metabolite of Arginine) and monitored for two months. Improvement will be noted on their response to the Neuropathic Pain Questionnaire. Additionally the investigators will note improvement by performing autonomic function testing at the beginning and end of the study.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Peripheral Neuropathy

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Men and Women Ages 18-75 with symptoms of small Fiber Neuropathy and have been diagnosed via autonomic function testing and or skin biopsy Exclusion Criteria: * Women who are pregnant or breast feeding, patients with history of substance abuse, and patients with myelopathy

Locations (1)

JFK Medical Center

Edison, New Jersey, United States

RECRUITING

Outcomes

Primary Outcomes

Neuropathic Pain Questionnaire

Time frame: After 2 months

Secondary Outcomes

QSART & ANSAR testing

Time frame: After 2 months

Central Contacts

Michael Rosenberg, MD

CONTACT

732-321-7010 mrosenberg@jfkhealth.org

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.